Biotech stocks took a beating in September. The bellwether funds iShares Biotechnology ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEMKT: XBI) both lost a significant chunk of their value last month. These two leading indicators hit the skids for two core reasons. First, the fallout from the Chinese property giant Evergrande and its financial woes weighed on small- to mid-cap drugmakers with a vengeance last month. Investors, in effect, went into risk-off mode following this news.
XBI data by YCharts.
For further details see:
2 Best Biotech Stocks to Buy In October